# First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct06622486/  
OnCo record `nct06622486` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of EGL-001 in advanced solid tumours, run by Egle Therapeutics, now recruiting.

## Summary

First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06622486 by Egle Therapeutics, with 50 participants planned, started 2024-09-27 and due to reach its primary completion in 2027-01-23. Interventions recorded: EGL-001.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06622486
- Phase: 1/2
- Setting: First-in-human Phase 1/2 Trial of EGL-001 in Adult Patients with Selected Advanced And/or Metastatic Solid Tumors
- Sponsor: Egle Therapeutics
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT06622486: https://clinicaltrials.gov/study/NCT06622486

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06622486.json